Physician profile
Dennis Booth
NPI 1639174741
$9,072.30
in general payments reported to CMS, 2019-2025
37 companies · $1,845 in 2025
The $1,845 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,010 · 2020: $416 · 2021: $964 · 2022: $1,546 · 2023: $1,777 · 2024: $1,514 · 2025: $1,845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,118 · Education: $17.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,118.00 |
| Education | $17.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,520.87 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Takeda Pharmaceuticals U.S.A., INC. | $944.61 | 2019-2025 | Entyvio |
| Genzyme Corporation | $678.21 | 2022-2025 | |
| Celgene Corporation | $581.91 | 2021-2024 | Zeposia |
| Pfizer INC. | $500.24 | 2019-2025 | |
| Qol Medical, LLC | $423.85 | 2019-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $218.06 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $216.73 | 2024-2025 | Dupixent |
| Janssen Biotech, INC. | $207.42 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.07 | 2019-2022 | |
| Boston Scientific Corporation | $170.22 | 2021-2022 | |
| Ardelyx, INC. | $158.95 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $158.04 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $143.24 | 2019-2024 | Dificid |
| Redhill Biopharma INC. | $131.73 | 2020-2023 | Aemcolo, Talicia, Movantik |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $115.93 | 2023-2025 | Vegzelma, Yuflyma |
| Allergan, INC. | $114.16 | 2019 | |
| Janssen Scientific Affairs, LLC | $91.31 | 2020 | |
| Amgen INC. | $62.80 | 2021-2023 | Avsola, Amjevita |
| Phathom Pharmaceuticals, INC. | $57.68 | 2025 | Voquezna |
| Ucb, INC. | $52.55 | 2019 | |
| Aimmune Therapeutics, INC. | $45.23 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $39.04 | 2024 | |
| Nestle Healthcare Nutrition INC. | $30.59 | 2022 | |
| Lilly USA, LLC | $27.62 | 2025 | Omvoh |
| Evoke Pharma, INC. | $26.89 | 2022-2023 | Gimoti |
| Braintree Laboratories, INC. | $25.16 | 2021-2023 | Sutab |
| Novo Nordisk INC | $21.08 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $18.20 | 2024 | |
| Ferring Pharmaceuticals INC. | $16.95 | 2023 | Rebyota |
| Organon LLC | $16.24 | 2023 | Hadlima |
| Mauna Kea Technologies, INC. | $16.01 | 2024 | |
| Pharmacosmos Therapeutics INC. | $15.47 | 2023 | Monoferric |
| Shire North American Group INC | $14.86 | 2019 | |
| Medtronic, INC. | $13.68 | 2024 | Interstim |
| Shionogi INC | $11.45 | 2019 | |
| Echosens North America, INC. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Booth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.